Search results for "MAb"

showing 10 items of 1716 documents

Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review

2003

Abstract Physicians are increasingly aware that asthma causes significant impairment of the patient's physical, psychological, and social well-being. Whilst standard clinical endpoints provide significant information on airway status during treatment, it is important to determine whether such improvements overcome the functional impairment that patients have to deal with on a daily basis. As such, assessment of health-related quality of life (QoL) is an important aspect of asthma management in clinical practice. Omalizumab (Xolair ® ) is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody that represents a new therapeutic approach to IgE-mediated diseases such as allergi…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EPlaceboTherapeutic approachDouble-Blind MethodQuality of lifeInternal medicinemedicineClinical endpointHumansAnti-Asthmatic Agentsanti-IgEChildquality of life.AgedAsthmabiologybusiness.industryRespiratory diseaseAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicQuality of Lifebiology.proteinPhysical therapyomalizumabbusinessAttitude to Healthallergic asthmamedicine.drugRespiratory Medicine
researchProduct

Aneurysmal bone cyst of the spine in adult patients: A systematic review and comparison of primary vs secondary lesions.

2021

Background: Spine aneurysmal bone cysts (ABCs) rarely occur in adults. Primary and secondary lesions may show some differences and require appropriate treatments. Objective: To systematically review the literature on adult spine ABCs. Methods: PubMed, EMBASE, Scopus, and Web-of-Science were searched. Clinical-radiological features, treatments, and outcomes were analyzed and compared between primary vs secondary adult spine ABCs. Results: We included 80 studies comprising 220 patients. Primary spine ABCs were more frequent (76.4%). Main symptoms were lower-back-pain (42.8%) and motor deficits (31.2%). Tumors were mostly thoracic (31.4%) or cervical (26.8%), showing lytic (70.4%) and/or cysti…

AdultSettore MED/27 - NeurochirurgiaGeneral MedicineEmbolization TherapeuticSpineEmbolizationBone Cysts AneurysmalNeurologyAneurysmal bone cystPhysiology (medical)HumansSurgeryNeurology (clinical)DenosumabNeoplasm Recurrence LocalRetrospective StudiesJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
researchProduct

Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.

2020

Background/methods At a consensus meeting in August 2018, pediatricians and dermatologists from German-speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE-C1-INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This art…

Adultmedicine.medical_specialtyAdolescentImmunology610610 Medicine & healthLanadelumabDiseaseC1-inhibitorGermanPlasma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIcatibantGermanymedicineHumansImmunology and Allergy030212 general & internal medicineAngioedemaChildIntensive care medicine610 Medicine & healthAngioedemabiologytreatmentbusiness.industryAngioedemas HereditaryC1-INH (C1 inhibitor)medicine.diseaselanguage.human_languagehereditary angioedemapediatric030228 respiratory systemchemistryconsensusPediatrics Perinatology and Child HealthHereditary angioedemalanguagebiology.proteinmedicine.symptombusinessComplement C1 Inhibitor Protein600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitRare disease
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovaria…

2013

Summary Background In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival. This study aims to describe the health-related quality-of-life (QoL) outcomes from ICON7. Methods ICON7 is a randomised, multicentre, open-label phase 3 trial. Between Dec 18, 2006, and Feb 16, 2009, after a surgical procedure aiming to debulk the disease, women with Inter…

Adultmedicine.medical_specialtyBevacizumabDrug-Related Side Effects and Adverse ReactionsAntibodies Monoclonal HumanizedDisease-Free Survivallaw.inventionchemistry.chemical_compoundRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedNeoplasm StagingOvarian NeoplasmsIntention-to-treat analysisbusiness.industryStandard treatmentArticlesMiddle Agedmedicine.diseaseCarboplatinSurgeryBevacizumabClinical trialTreatment OutcomeOncologychemistryQuality of LifeFemaleOvarian cancerbusinessmedicine.drugThe Lancet Oncology
researchProduct

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multice…

2021

none 38 no BACKGROUND: Natalizumab (NTZ) is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). However, patients and physicians may consider discontinuing NTZ therapy due to safety or efficacy issues. The aim of our study was to evaluate the NTZ discontinuation rate and reasons of discontinuation in a large Italian population of RRMS patients. MATERIALS AND METHODS: The data were extracted from the Italian MS registry in May 2018 and were collected from 51,845 patients in 69 Italian multiple sclerosis centers. MS patients with at least one NTZ infusion in the period between June 1st 2012 to May 15th 2018 were included. Discontinuation rates at each time point were cal…

Adultmedicine.medical_specialtyDiscontinuation rateNeurologyReasons for discontinuationPopulationProgressive MultifocalRelapsing-RemittingSettore MED/26Multiple sclerosis03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingLeukoencephalopathyInternal medicineparasitic diseasesmedicineEffective treatmentHumansImmunologic FactorsMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDiscontinuation rate; Multiple sclerosis; Natalizumab; Reasons for discontinuation; Adult; Female; Humans; Immunologic Factors; Middle Aged; Natalizumab; Retrospective Studies; Leukoencephalopathy Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis Relapsing-Remittingbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyNatalizumabLeukoencephalopathy Progressive MultifocalRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.

2005

Background & Aims: Azathioprine is the gold standard for immunosuppressive therapy in Crohn's disease (CD) and its molecular mechanism of action is caused by the metabolite 6-thioguanosine triphosphate (TGTP). In this study we assessed the impact of TGTP levels for monitoring of azathioprine therapy. Methods: A novel, highly sensitive assay was established to measure levels of TGTP and its precursors 6-thioguanosine monophosphates and 6-thioguanosine diphosphates (TGDP) in red blood cells from 50 CD patients. The results were correlated with clinical outcome. Results: TGTP levels could be quantified in 47 patients and a subgroup of these patients showed significantly high levels of TGDP. 6-…

Adultmedicine.medical_specialtyErythrocytesMetaboliteAzathioprineInflammatory bowel diseaseGastroenterologyGuanosine Diphosphatechemistry.chemical_compoundCrohn DiseaseInternal medicineAzathioprinemedicineHumansCrohn's diseaseHepatologyThiopurine methyltransferasebiologybusiness.industryGastroenterologyAzathioprine therapyAntibodies MonoclonalThionucleotidesmedicine.diseaseInfliximabGuanine NucleotidesInfliximabRed blood cellmedicine.anatomical_structurechemistryImmunologybiology.proteinbusinessBiomarkersImmunosuppressive Agentsmedicine.drugClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

2020

Abstract Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with…

Adultmedicine.medical_specialtyExacerbationmedicine.medical_treatmentThrombotic thrombocytopenic purpuraMedizin030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicineHumansRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpuraPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain Antibodiesmedicine.diseasePurpuraDisease PresentationCardiovascular and Metabolic Diseases030220 oncology & carcinogenesisCaplacizumabmedicine.symptombusiness
researchProduct

Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study

2021

Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a clinical entity with specific features that impacts significantly on patient quality of life (QoL). CRSwNP is often associated with asthma and is difficult to control and manage despite pharmacological and/or surgical treatment. Omalizumab, a monoclonal anti-IgE antibody, has emerged as a putative therapeutic option. Objective To evaluate the effects of omalizumab on nasal polyp (NP) size and QoL assessed by Sino-Nasal Outcome Test-22 (SNOT-22) in patients with recalcitrant CRSwNP and mild asthma. Methods A multicenter retrospective analysis of patient data from the Community of Valencia (Spain) was performed. Adult patients …

Adultmedicine.medical_specialtyMild asthmaOmalizumabOmalizumabaspirin-exacerbated respiratory diseasechronic rhinosinusitis with nasal polypsImmunoglobulin E03 medical and health sciencesNasal Polyps0302 clinical medicineQuality of lifeSNOT-22Internal medicinemedicineHumansImmunology and AllergyNasal polypsIn patient030223 otorhinolaryngologyRetrospective StudiesRhinitisnasal polypsbiologybusiness.industrytotal nasal endoscopic polyp scoreRetrospective cohort studyGeneral Medicinemedicine.diseaseAsthmaTreatment Outcomequality of lifetissue eosinophilia030228 respiratory systemOtorhinolaryngologyIgE SNOT-22 aspirin-exacerbated respiratory disease chronic rhinosinusitis with nasal polyps mild asthma nasal polyps omalizumab quality of life tissue eosinophilia total nasal endoscopic polyp scoreChronic DiseaseQuality of Lifebiology.proteinomalizumabAspirin exacerbated respiratory diseaseIgEbusinessmild asthmamedicine.drugAmerican Journal of Rhinology & Allergy
researchProduct

Hemorheological profile in primary and secondary Raynaud's phenomenon. Influence of microangiopathy.

2013

Raynaud's phenomenon (RP) is an episodic peripheral circulatory disorder characterized by local artery spams in subjects exposed to cold or emotional stress. It is not well-established whether RP patients show an altered rheological profile, mostly due to patient classification and clinical severity. We aimed to compare the hemorheological profile in patients with primary and secondary RP with a healthy control group. Eighteen primary RP, 22 secondary RP and 22 healthy controls, were included in the study. RP patients were also divided according to the presence of digital ulcers (7 with, 33 without). Biochemical and hemorheological variables were analyzed, including glucose, triglycerides, …

Adultmedicine.medical_specialtyPhysiologyBlood viscosityFibrinogenGastroenterologyErythrocyte aggregationYoung AdultPhysiology (medical)Internal medicinemedicineErythrocyte deformabilityHumansAgedbusiness.industryMicroangiopathyRaynaud DiseaseHematologyMiddle Agedmedicine.diseaseBlood ViscositySurgerymedicine.anatomical_structureCirculatory systemHemorheologyHemorheologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugArteryClinical hemorheology and microcirculation
researchProduct